Relevant Facts until February 8th, 2020

2019 12 30 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 12 23 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 12 16 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 12 09 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 12 02 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 11 25 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 11 18 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 11 11 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 11 04 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 10 28 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 10 21 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 10 14 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 10 07 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 09 30 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 09 23 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 09 16 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 09 09 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 09 02 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 08 19 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 08 05 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 07 29 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)

2019 07 25 – Reig Jofre closes the first half of 2019 with a sales growth of 3% and EBITDA of 6% (PDF)

2019 07 22 – First tranche of the second share buyback program (PDF)

2019 07 01 – Reig Jofre acquires Bioibérica’s portfolio of finished pharmaceutical and nutraceutical products (PDF)

2019 06 21 – Start date of trading for the new shares resulting from the capital increase (PDF)

2019 06 17 – Reig Jofre informs on the results of the increase of the share capital (PDF)

2019 06 13 – Reig Jofre informs on the increase of the Company’s share capital (PDF)

2019 06 12 – Reig Jofre informs on the start date of the trading of the new shares within its scrip dividend (PDF)

2019 05 31 – Reig Jofre informs on the bonus-shares capital increase and the new shares to be issued (PDF)

2019 05 06 – Reig Jofre informs on the execution of the scrip dividend (PDF)

2019 04 25 – Reig Jofre informs on the conditions of the scrip dividend (PDF)

2019 04 25 – Reig Jofre informs on the resolutions adopted in 2019 Shareholders’ Meeting (PDF)

2019 03 25 – Reig Jofre convenes the Ordinary General Shareholders’ Meeting (PDF)

2019 03 25 – Reig Jofre informs on the convening of its 2019 General Shareholders´ Meeting (PDF)

2019 02 28 – Results preview: Year 2018 (PDF)

2019 01 23 – Publication schedule for 2019 results (PDF)

2018 12 03 – Transactions within the shares buyback program (PDF)

2018 11 26 – Transactions within the shares buyback program (PDF)

2018 11 19 – Transactions within the shares buyback program (PDF)

2018 11 12 – Transactions within the shares buyback program (PDF)

2018 11 05 – Transactions within the shares buyback program (PDF)

2018 10 29 – Transactions within the shares buyback program (PDF)

2018 10 22 – Transactions within the shares buyback program (PDF)

2018 10 15 – Transactions within the shares buyback program (PDF)

2018 10 08 – Transactions within the shares buyback program (PDF)

2018 09 28 – Transactions within the shares buyback program (PDF)

2018 09 24 – Transactions within the shares buyback program (PDF)

2018 09 17 – Transactions within the shares buyback program (PDF)

2018 09 10 – Transactions within the shares buyback program (PDF)

2018 09 06 – Reig Jofre informs on the launch of Remikaf in Indonesia (PDF)

2018 09 03 – Transactions within the shares buyback program (PDF)

2018 08 27 – Transactions within the shares buyback program (PDF)

2018 08 20 – Transactions within the shares buyback program (PDF)

2018 08 03 – Transactions within the shares buyback program (PDF)

2018 08 03 – Start of the trading of the new shares following the scrip dividend (PDF)

2018 07 30 – Transactions within the shares buyback program (PDF)

2018 07 25 – Reig Jofre informs on the start of the third Temporary Share Buyback Program (PDF)

2018 07 17 – Scrip dividend: bonus-shares capital increase and new shares to be issued (PDF)

2018 06 27 – Forté Pharma strengthens its leadership in weight control in France (PDF)

2018 06 21 – Reig Jofre informs on the start of coverage through three equity research reports (PDF)

2018 06 14 – Scrip dividend: beginning of the trading period of the allotment rights (PDF)

2018 06 07 – Remuneration through the scrip dividend or flexible dividend (PDF)

2018 05 03 – Resolutions on the general shareholders’ meeting (PDF)

2018 04 09 – Reig Jofre informs on the € 30M investment plan to expand its injectable products plant of Barcelona (PDF)

2018 03 23 – Reig Jofre convenes the Ordinary General Shareholders’ Meeting (PDF)

2018 03 23 – Reig Jofre and Leanbio create the joint venture Syna Therapeutics for the development of biosimilar products (PDF)

2018 02 20 – Reig Jofre informs on the presentation of 2017 results (PDF)

2018 01 26 – Publication schedule for 2018 results (PDF)

2018 01 24 – Launch in France of a new nutritional supplement of Forté Pharma (PDF)

2018 01 05 – Transactions within the shares buyback program (PDF)

2018 01 03 – Transactions within the shares buyback program (PDF)

2017 12 29 – Administrative merger by absorption (PDF)

2017 12 15 – Transactions within the shares buyback program (PDF)

2017 12 11 – Transactions within the shares buyback program (PDF)

2017 12 01 – Transactions within the shares buyback program (PDF)

2017 11 13 – Appointment of Alain Boutboul as General Manager of Forté Pharma (PDF)

2017 11 10 – Appointment of Mr. Alejandro Garcia Reig, as Vice President of Reig Jofre (PDF)

2017 11 07 – Transactions within the shares buyback program (PDF)

2017 10 31 – Reig Jofre informs on the expansion of the product portfolio of Forté Pharma (PDF)

2017 10 26 – Appointments at the head of the corporate and financial management of the Company (PDF)

2017 10 24 – Transactions within the shares buyback program (PDF)

2017 10 24 – Reig Jofre informs on the first social-health research worldwide on the use of seawaters in respiratory tract diseases (PDF)

2017 09 10 – Transactions within the shares buyback program (PDF)

2017 09 26 – Transactions within the shares buyback program (PDF)

2017 09 13 – Reig Jofre informs on the launch of Otospray (PDF)

2017 09 07 – Admission to trading of the new shares from the scrip dividend (PDF)

2017 09 06 – New commercial activity in the Philippines (PDF)

2017 09 04 – Transactions within the shares buyback program (PDF)

2017 08 22 – Transactions within the shares buyback program (PDF)

2017 07 25 – Reig Jofre informs about the new shares (PDF)

2017 07 24 – Transactions within the shares buyback program (PDF)

2017 07 18 – Transactions within the shares buyback program (PDF)

2017 07 10 – Transactions within the shares buyback program (PDF)

2017 07 05 – Transactions within the liquidity contract in Q2 2017 (PDF)

2017 07 04 – Reig Jofre informs on the end of the commitments between the Company and Naturex SA (PDF)

2017 07 03 – Reig Jofre informs about its scrip dividend (PDF)

2017 06 30 – Reig Jofre informs about second shares buy-back program (PDF)

2017 06 15 – Begining of the trading period of free allotment rights (PDF)

2017 06 08 – Conditions for the execution of the capital increase through the scrip dividend or flexible dividend (PDF)

2017 06 08 – Resolutions on the general shareholders’ meeting (PDF)

2017 05 03 – Convening of the Ordinary and Extraordinary General Shareholders’ Meeting (PDF)

2017 05 03 – Reig Jofre, strategic partner in the stabilization and production of the first veterinary vaccine against Leishmaniasis (PDF)

2017 04 06 – Transactions within the liquidity contract in Q1 2017 (PDF)

2017 03 30 – Reig Jofre informs on the inauguration of a new development and quality control laboratory (PDF)

2017 03 23 – Reig Jofre informs on the marketing of three new injectable products for hospitals (PDF)

2017 03 16 – Reig Jofre informs on the involvement with emerging biotech companies and research centers (PDF)

2017 02 23 – Reig Jofre informs on the public deed of capital reduction (PDF)

2017 02 20 – Reig Jofre informs on the presentation of 2016 results (PDF)

2017 02 15 – Reig Jofre launches a new product development in the dermatology area (PDF)

2017 02 10 – Forte Pharma honored in Hong Kong with the award “Health Wellness Beauty 2016” (PDF)

2017 01 30 – Publication schedule for 2017 results (PDF)

2017 01 09 – Transactions within the liquidity contract in Q4 2016 (PDF)

2017 01 03 – Transactions within the shares buyback program (PDF)

2016 12 27 – Transactions within the shares buyback program (PDF)

2016 12 20 – Transactions within the shares buyback program (PDF)

2016 11 23 – Transactions within the shares buyback program (PDF)

2016 11 14 – Transactions within the shares buyback program (PDF)

2016 10 25 – Transactions within the shares buyback program (PDF)

2016 10 18 – Transactions within the shares buyback program (PDF)

2016 10 11 – Transactions within the shares buyback program (PDF)

2016 10 03 – Transactions related to the liquidity contract (PDF)

2016 10 03 – Transactions within the shares buyback program (PDF)

2016 09 26 – Transactions within the shares buyback program (PDF)

2016 09 20 – Transactions within the shares buyback program (PDF)

2016 09 13 – Transactions within the shares buyback program (PDF)

2016 09 06 – Transactions within the shares buyback program (PDF)

2016 08 08 – Equity reorganisation (PDF)

2016 07 25 – Program of Shares Buyback (PDF)

2017 07 22 – Reig Jofre strengthens its workforce and exceeds 910 employees (PDF)

2016 07 08 – Transactions within the liquidity contract in Q2 2016 (PDF)

2016 06 23 – Resolutions on the general shareholders’ meeting (PDF)

2016 06 07 – Allocation of treasury stock to the acquisition of Biotech Geadic

2016 05 21 – Convening of the Ordinary and Extraordinary General Shareholders’ Meeting

2016 05 20 – Reformulation of the individual and consolidated financial statements for the year 2015

2016 04 06 – Transactions within the liquidity contract in Q1 2016

2016 02 29 – Results preview: Year 2015

2016 02 23 – Reig Jofre certified by the Japanese agency for the manufacture of a sterile injectable for hospital use

2016 02 17 – Reig Jofre will present 2015 results

2016 02 02 – Reig Jofre strengthens its portfolio of sterile injectable products with the acquisition of a sodium heparin

2016 01 25 – Schedule of 2016 results releases

2016 01 20 – Reig Jofre strengthens its Respiratory/ENT range with the exclusivity license for Spain of Sterimar®

2016 01 04 – New liquidity contract with Solventis AV SA

2015 12 21 – Notification of the member state of origin (PDF)

2015 12 18 – Changes in the Board of Directors (PDF)

2015 11 16 – Treasury stock transactions 9M 2015 (PDF)

2015 11 11 – Appointment of Frederic Dingeon as head of the antibiotics development and production business unit (PDF)

2015 10 30 – Reorganization of the delegated committees of the Board of Directors (PDF)

2015 10 15 – Reig Jofre starts national and international presentation roadshow (PDF)

2015 09 22 – Execution of the cancellation and consolidation of shares (reverse split) (PDF)

2015 09 17 – Collaboration agreement with the biotechnological company Manremyc (PDF)

2015 09 15 – Clarification on the reverse split date (PDF)

2015 08 24 – Resignation of Natra from the board of directors (PDF)

2015 08 17 – Treasury stock transactions 6M 2015 (PDF)

2015 07 31 – Implementation procedures of the reverse split (PDF)

2015 07 27 – Reig Jofre increases capital for the entry of Cofides into the share capital of Reig Jofre UK Ltd. (PDF)

2015 07 27 – Cofides supports Reig Jofre international development (PDF)

2015 07 14 – Reig Jofre announces conference on the six-month results of 2015 (PDF)

2015 06 22 – Schedule of the reverse split (PDF)

2015 06 12 – Resolutions on the general shareholders’ meeting (PDF)

2015 05 18 – Treasury stock operations 3M 2015 (PDF)

2015 05 11 – Convening of General Shareholders’ Meeting 2015 (PDF)

2015 04 14 – Treasury stock operations Q1 2015 (PDF)

2015 04 08 – Acquisition of marketing authorisations in United Kingdom (PDF)

2015 03 28 – Answers to unaddressed questions from 2014 results webcast (PDF)

2015 03 23 – Documentation of the conference presentation on 2014 pro forma results (PDF)

2015 03 18 – Schedule of 2015 results releases (PDF)

2015 03 12 – Conference announcement on 2014 proforma results (PDF)

2015 03 08 – Commercial agreement in Japan (PDF)

2015 02 25 – Release by the Board of Directors regarding the sharp rise of RJF trading price (PDF)

2015 02 18 – New corporate website and image (PDF)

2015 02 16 – Conclusion of requirements regarding the merger between Reig Jofre and Natraceutical (PDF)

2015 02 13 – Liquidity contract (PDF)

2015 02 12 – Listing of new shares and change of trading ticker (PDF)

2015 02 03 – Register of the merger in the Commercial Registry of Barcelona (PDF)

2015 01 16 – Appointment of Chairman and CEO and constitution of delegate committees (PDF)

2014 12 31 Register of public deed of the merger with Laboratorio Reig Jofre SA (PDF)

2014 12 18 Execution of public deed of the merger with Laboratorio Reig Jofre SA (PDF)

2014 12 01 Request for the exemption of TOB (PDF)

2014 12 01 End period of opposition from creditors (PDF)

2014 10 29 Publication of merger announcements with Laboratorio Reig Jofre (PDF)

2014 10 24 Resolutions of the General Extraordinary Shareholders’ Meeting (PDF)

2014 10 22 Confirmation of the call for the General Extraordinary Shareholders’ Meeting (PDF)

2014 10 21 Pro forma financial statements as of June 30, 2014 (PDF)

2010 10 15 Documents of the presentation event on the merger project with Laboratorio Reig Jofre (PDF)

2014 09 30 Announcement of public presentations on the merger project with Laboratorio Reig Jofre (PDF)

2014 09 22 Convening of the Extraordinary General Shareholders’ Meeting (PDF)

2014 07 01 Resolutions of the General Shareholders’ Meeting (PDF)

2014 06 27 Date change of the 2014 first half results (PDF)

2014 06 26 Merger between Natraceutical and Laboratorio Reig Jofre (PDF)

2014 06 26 Merger project between Natraceutical and Laboratorio Reig Jofre (PDF)

2014 06 26 Merger protocol between Natraceutical and Laboratorio Reig Jofre (PDF)

2014 05 23 Convening of the Shareholders’ General Meeting 2014 (PDF)

2014 04 24 Resignation of Felix Revuelta as member of the board of directors (PDF)

2014 03 04 Resignation of director Natra, SA and appointment of Galo Álvarez (PDF)

2014 01 21 Results release schedule for 2014 (PDF)

2014 01 10 Resignation of Ibersuizas and Mª Teresa Lozano from the board of directors (PDF)